Genetic testing for alpha thalassaemia - amendment to Pathology MBS item 73410

This page provides information regarding the amendment to pathology MBS item 73410 for genetic testing for alpha thalassaemia that will apply from 1 November 2022

Page last updated: 25 October 2022

From 1 November 2022, the descriptor for MBS item 73410 will be amended to clarify that patients with beta thalassaemia can access Medicare funded genetic testing for the diagnosis of alpha thalassaemia.

The change was recommended by the Medical Services Advisory Committee Executive to align the item with standard clinical practice.

Further information is available in the following factsheet:

PDF Version 1 November 2022 amendment to pathology MBS item 73410 (PDF 141 KB)
Word Version 1 November 2022 amendment to pathology MBS item 73410 (Word 119 KB)

In this section